- Protocol Short Name and Number: S2213, 2205
- Protocol Long Name: A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosi
- Key Personnel
- Study Chairs:
- Patrick Hagen, MD, MPH
- Surbhi Sidana, MD
- Terri Parker, MD
- Brian Walker, BSc, PhD
- Protocol Champions:
- Anita D’Souza, MD [BMT CTN]
- Heather Landau, MD [Alliance]
- Taxiarchis Kourelis, MD [ECOG-ACRIN]
- SWOG Protocol Coordinator: Sharon Palmer, spalmer@swog.org
Note: For the SWOG S2213 / BMT CTN 2205 study, the BMT CTN is endorsing the study and providing accrual credit. Centers participate via their NCTN group. BMT CTN Centers will receive both NCTN and BMT CTN accrual credits. The protocol may be accessed through the CTSU website: https://www.ctsu.org. For questions about the study and how to participate, contact the SWOG protocol coordinator, Sharon Palmer, spalmer@swog.org or the CTSU Help Desk at ctsucontact@westat.com or 1 888 823-5923.